Vor Biopharma, Inc. (VOR)

Vor Biopharma's stock has experienced significant volatility and events in the past six months. The share price declined by 53.88% from February 4, 2025, to February 3, 2026. On September 18, 2025, the stock underwent a 1-20 reverse split. In June 2025, a licensing agreement with RemeGen for telitacicept led to a 265.5% surge in shares. A recent capital offering negatively impacted the stock outlook due to share dilution. Q2 2025 earnings missed analysts' estimates, while Q3 2025 earnings exceeded expectations. Andrew Levin and Wouter Joustra were appointed to the Board of Directors on December 23, 2025. Jean-Paul Kress was appointed as the new CEO and chairman in June 2025. Vor Biopharma's CDO departed on January 4, 2026. Vor Bio participated in several healthcare conferences.

There is no specific information available regarding demand seasonality for Vor Biopharma, Inc.'s products and services. Demand for its products is typically driven by medical need rather than seasonal fluctuations.

Vor Biopharma, Inc. is a clinical-stage cell therapy company focused on transforming cancer treatment, particularly for hematological malignancies, operating within the Health Technology sector and Biotechnology industry. The company's core business is centered on its Chimeg platform, which facilitates the development of engineered T-cell therapies. Its major products and pipeline candidates include Trem-cel, an engineered hematopoietic stem cell product candidate, VCAR33, and Telitacicept, a novel dual-target fusion protein licensed from RemeGen.

Vor Biopharma, Inc. is headquartered in Boston, Massachusetts, with another location in Cambridge, Massachusetts. The company's development and commercialization efforts for telitacicept extend to ex-China markets, including the United States, Europe, and South America.

Vor Biopharma generally holds a "Moderate Buy" consensus rating from analysts. Strategic enhancements in asset management, financial stability, and leadership are viewed positively. Positive efficacy comparisons and a favorable safety profile of its product offerings suggest a higher likelihood of adoption and market penetration. However, a significant reduction in the 12-month price target indicates investor concerns regarding the company's valuation and financial health. Potential challenges with product enrollment and decreased immunoglobulin levels raise uncertainties about the long-term viability of their therapies.

Vor Biopharma Inc. has 67 institutional owners and shareholders holding a total of 5,334,738 shares. Major institutional owners include RA Capital Management LP, Forbion Capital Partners Management Holding BV, Frazier Management LLC, Susquehanna International Group, Llp, Vanguard Group Inc., Shay Capital LLC, QVG2Q - Growth Portfolio Investor Class, VR Adviser, LLC, Fcpm Iii Services B.v., Paradigm BioCapital Advisors LP, Great Point Partners LLC, Reprogrammed Interchange LLC, UBS Group AG, and Fidelity Select Portfolios - Biotechnology Portfolio. Institutions hold 97.29% of the stock, while insiders hold 0.45%.